0001390478-26-000008
SEC filingQ1 operating and net losses widened versus prior year amid late-stage oncology trial investments, reflecting higher development costs from increased trial size and duration, partially offset by stronger interest income on elevated cash balances.
SELLAS Life Sciences Group reported wider GAAP operating and net losses in Q1 FY2026, driven by the inherently higher costs of advancing oncology candidates into later-stage clinical development. Operating income deteriorated 52.6% to -$9.3 million from -$6.1 million year-over-year, as trials like the REGAL study for GPS and Phase 2 for SLS009 in front-line AML necessitate larger patient cohorts and extended timelines compared to earlier phases. This aligns with management's outlook for escalating research and development expenses to support a potential BLA filing for GPS post-final REGAL analysis and to progress SLS009 enrollment per FDA guidance.
Cash from operations improved marginally to -$8.8 million from -$9.1 million, reflecting more favorable working capital timing despite the deeper bottom-line loss. With no revenue from product sales in either period, SELLAS remains funded through non-dilutive interest and equity inflows, underscoring its clinical-stage profile.
Looking forward, management anticipates sustained R&D growth to complete ongoing trials and initiate others, alongside rising professional fees for corporate expansion and commercialization readiness. These investments position GPS and SLS009 for key milestones like REGAL readout and front-line AML data, balancing elevated burn against potential regulatory progress in a capital-intensive biotech landscape.